This Product cannot be purchased without a prescription

CYTOPOINT® solution for injection for dogs - Pet Health Direct
CYTOPOINT solution for injection for dogs - Pet Health Direct
CYTOPOINT solution for injection for dogs - Pet Health Direct
CYTOPOINT solution for injection for dogs - Pet Health Direct
CYTOPOINT solution for injection for dogs - Pet Health Direct
  • Load image into Gallery viewer, CYTOPOINT® solution for injection for dogs - Pet Health Direct
  • Load image into Gallery viewer, CYTOPOINT solution for injection for dogs - Pet Health Direct
  • Load image into Gallery viewer, CYTOPOINT solution for injection for dogs - Pet Health Direct
  • Load image into Gallery viewer, CYTOPOINT solution for injection for dogs - Pet Health Direct
  • Load image into Gallery viewer, CYTOPOINT solution for injection for dogs - Pet Health Direct

CYTOPOINT solution for injection for dogs

Regular price
£89.99
Sale price
£89.99
Regular price
Sold out
Unit price
per 
Tax included. Shipping calculated at checkout.
0%

Are you aware of the relevant safety precautions relating to the product?

Have you used this before?

Before this medication can be dispensed you will need to log in and select the pet that it is for. Click here to login

Canine Atopic Dermatitis Immunotherapeutic

For Use in Dogs Only

Cytopoint aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

Cytopoint is a ready-to-use, sterile liquid containing a caninized monoclonal antibody (mAb) against interleukin-31 (IL-31). IL-31 has been shown to induce pruritus in dogs in laboratory studies.

Cytopoint remains in circulation for several weeks. It exerts a therapeutic effect by binding to and neutralizing soluble IL-31, thus inhibiting pruritus and reducing skin lesions. Like other naturally-occurring antibodies and antibody-antigen complexes, elimination is via normal protein degradation pathways.

SAFETY: A field safety study has demonstrated that Cytopoint is well tolerated in dogs after subcutaneous injection. Adverse events occurred at a similar frequency between treated and placebo groups in a study of 245 canine patients presented to veterinary hospitals and diagnosed with atopic dermatitis. In this study, dogs were administered Cytopoint(1.0-3.3 mg/kg body weight) or placebo by the subcutaneous route on Days 0 and 28. Signs of patient discomfort on administration and adverse events occurred at a similar frequency between treatment groups. In addition, there was no clinically important difference in clinical pathology changes between groups following either dose. A wide variety of concomitant medications were safely used, including parasiticides, antibiotics, antifungals, corticosteroids, vaccines, immunotherapy, antihistamines and other antipruritics, such as oclacitinib and cyclosporine.

This product is sourced in the United Kingdom and is intended for use in the United Kindgom only.

Datasheets:

CYTOPOINT® solution for injection for dogs